Results 21 to 30 of about 207,642 (302)
Neuropsychopharmacology Reports, 2020 Aim A substantial proportion of major depressive disorder patients are treatment‐resistant to antidepressant therapy, who require augmentation drugs, or other treatments including electroconvulsive therapy or transcranial magnetic stimulation ...
Katsuhiko Yamasaki +2 more
doaj +1 more source
SUMOylation and Major Depressive Disorder
International Journal of Molecular Sciences, 2022 Since the discovery of the small ubiquitin-like modifier (SUMO) protein in 1995, SUMOylation has been considered a crucial post-translational modification in diverse cellular functions. In neurons, SUMOylation has various roles ranging from managing synaptic transmitter release to maintaining mitochondrial integrity and determining neuronal health.
Seok-Won Jeoung +5 more
openaire +2 more sources
Depression from the perspective of modern and Persian medicine
Electronic Physician, 2018 Background: Depression is one of the five most-common diseases globally, and is expected to be the second leading cause of disability by 2020 and its economic and social burden is a major problem worldwide Objective: The aim of this research was to ...
Majid Anushiravani +3 more
doaj +1 more source
Non-REM sleep in major depressive disorder
NeuroImage: Clinical, 2022 Disturbed sleep is a key symptom in major depressive disorder (MDD). REM sleep alterations are well described in the current literature, but little is known about non-REM sleep alterations.
Leonore Bovy +7 more
doaj +1 more source
Depression: Special Considerations for the Dental Setting
MedEdPORTAL, 2011 The 1-year prevalence rate for depression is 9.5%, or approximately 20.9 million adults in America. The lifetime prevalence of major depressive disorder is approximately 10%-25%.
Jessica G. Hinz
doaj +1 more source
Brazilian Journal of Psychiatry, 2022 Objective: To evaluate the impact of defense mechanisms at baseline on depressive symptoms after brief psychotherapies and after 6-months of follow-up among depressed patients with and without cluster B personality disorders (PDs).
Carolina Rheingantz Scaini +8 more
doaj +1 more source
Retinoid homeostasis in major depressive disorder
Translational Psychiatry, 2023 The small, hormone-like molecule retinoic acid (RA) is a vital regulator in several neurobiological processes that are affected in depression. Next to its involvement in dopaminergic signal transduction, neuroinflammation, and neuroendocrine regulation ...
Lisa Rebecca Otto +5 more
doaj +1 more source
Epigenetic prediction of major depressive disorder [PDF]
Molecular Psychiatry, 2020 AbstractVariation in DNA methylation (DNAm) is associated with lifestyle factors such as smoking and body mass index (BMI) but there has been little research exploring its ability to identify individuals with major depressive disorder (MDD). Using penalised regression on genome-wide CpG methylation, we tested whether DNAm risk scores (MRS), trained on ...
Ian J. Deary +13 more
openaire +7 more sources
Bilişsel Davranışçı Psikoterapi ve Araştırmalar Dergisi, 2014 Objective: The aim of this study is assessment of sexual dysfunction in female patients with major depressive disorder and panic disorder and compare the two groups. Methods: Total 76 female patients with primary diagnosis of major depressive disorder (
Tonguç Demir Berkol +5 more
doaj +1 more source
FEBS Letters, EarlyView.Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu +17 more
wiley +1 more source